VLST, Pfizer sign in-licensing agreement for oncology compound

VLST, has announced an in-licensing agreement for an anti-CD40 monoclonal antibody, CP-870,893, with Pfizer. As per the agreement, Pfizer will hold co-exclusive rights to CP-870,893 in the oncology vaccine field while VLST considers advancing the oncology compound into efficacy studies.